Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.

Constantin RiegerJörg SchlüchtermannEnno StorzLucas KastnerDavid Johannes Karl Paul Pfister Axel Heidenreich

Published in: BJU international (2024)

Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.

Keyphrases

muscle invasive bladder cancer
locally advanced
advanced non small cell lung cancer
radiation therapy
rectal cancer